People being treated for cancer may be at elevated risk of developing severe cases of COVID-19. The coronavirus is also affecting how cancer care is delivered.

by William G. Nelson, MD, PhD

Cancer centers are taking advantage of their in-house molecular laboratories to selectively test certain cancer patients for the coronavirus.

by Anna Azvolinsky

Forward Look

Recommendations address conflicts and research gaps.

by Ashley P. Taylor

Forward Look

Patients may be wary of discussing this common side effect.

by Sue Rochman

Forward Look

A new way to detect Barrett's esophagus.

by Bradley Jones

A gene-editing tool called CRISPR holds promise for treating cancer. What does the new technology mean for patients?

by Stephen Ornes

Pancreatic cancer remains a difficult disease to treat and is expected to be the second leading cause of U.S. cancer-related deaths by 2030. Researchers hope clinical trials and insights into the genetics of the disease will reverse the trend.

by Kendall K. Morgan

Policy Matters

Cancer outcomes are changing for the better, but advances are not affecting all patients equally.

by Brian Rivers, PhD

The National Cancer Institute and the Food and Drug Administration have provided guidance for managing clinical trials amid the spread of the novel coronavirus. Cancer centers are making changes to care for some patients enrolled in trials.

by Anna Azvolinsky

From the Editor-in-Chief

Emerging insights into epigenetic abnormalities in cancer cells may lead to better cancer outcomes.

by William G. Nelson, MD, PhD